research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Androgenic Effects on Ventricular Repolarization
ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
research Prevalence and associated factors of skin diseases in aged nursing home residents: a multicentre prevalence study
Nearly all elderly nursing home residents had a skin disease, with dry skin being the most common.
research Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment
Scalp cooling significantly reduces hair loss in chemotherapy patients.
research Tofacitinib for the treatment of alopecia areata in preadolescent children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
research Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial
PRP treatment improves hair density and thickness for alopecia, but needs more research.
research Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia
Dutasteride safely promotes hair growth and reduces hair loss, with mild side effects.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women
Both Platelet-Rich Plasma and Minoxidil foam increase hair count in women with hair loss, but Minoxidil is more effective. However, women were more satisfied with Platelet-Rich Plasma treatment.
research A 3-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Ability of an Extra-Strength Marine Protein Supplement to Promote Hair Growth and Decrease Shedding in Women with Self-Perceived Thinning Hair
An extra-strength marine protein supplement helped increase hair growth and decrease hair shedding in women with thinning hair.
research Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.
research Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
research Minoxidil 2% lotion for eyebrow enhancement: A randomized, double-blind, placebo-controlled, spilt-face comparative study
Minoxidil 2% lotion is safe and effective for making eyebrows thicker and fuller.
research Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
St. John's wort skin oil may increase skin damage risk during radiotherapy.
research Efficacy and safety of minoxidil 3% lotion for beard enhancement: A randomized, double‐masked, placebo‐controlled study
Minoxidil 3% lotion is effective and safe for increasing beard hair count.
research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
research Effectiveness of fractional erbium–YAG laser, microneedling, platelet-rich plasma in localized stable vitiligo patients: randomized clinical trial
Fractional Er:YAG laser with PRP is more effective and has fewer side effects than microneedling with PRP for vitiligo.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Safety and efficacy of oral administrated cepharanthine in non-hospitalized, asymptomatic or mild COVID-19 patients: a Double-blind, randomized, placebo-controlled trial
Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.
research Post-Finasteride Syndrome: About 2 Cases and Review of the Literature
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
research 491 Efficacy of oral tofacitinib in the treatment of lichen planopilaris
Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
research 0914 Association Between Obstructive Sleep Apnea, Nightmare Disorder and Incident Herpes Zoster
People with obstructive sleep apnea are more likely to get herpes zoster, but nightmares don't affect the risk.
research Efficacy of tofacitinib in pediatric alopecia universalis
Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
research TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.